Malvern Panalytical, a subsidiary of Spectris Plc (LON: SXS) (“Spectris“), providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, announced on 11 January 2021 the acquisition of Creoptix AG, a specialist bioanalysis sensor company.
The acquisition forms a critical part of Malvern Panalytical’s strategy to expand its capabilities in support of drug discovery.
Creoptix is a company headquartered in Wädenswil, near Zurich, Switzerland, with a US office in the Boston area. Creoptix was founded in 2009 and has successfully gone through several financing rounds with Eduard Brunner from Start Angels Network, Privilège Ventures and Swisscanto (CH) Private Equity Switzerland Growth I Fund, respectively, as lead investors. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix® WAVEsystem provides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and other molecules even in biofluids like undiluted serum or plasma.
EC M&A acted as financial advisor to Spectris on this transaction. This represents the 8th transaction EC M&A executed on behalf of Spectris.